Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of...
Saved in:
Main Authors: | Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/66aad92b4f694e8eb652eb40ee06dae7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
by: Yannuzzi NA, et al.
Published: (2019) -
Side Effects of Brolucizumab
by: Tahmineh Motevasseli, et al.
Published: (2021) -
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
by: Chakraborty D, et al.
Published: (2021) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016) -
Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
by: Pedrosa AC, et al.
Published: (2016)